| The biological properties of cetuximab B Vincenzi, G Schiavon, M Silletta, D Santini, G Tonini Critical reviews in oncology/hematology 68 (2), 93-106, 2008 | 175 | 2008 |
| Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a … B Vincenzi, M Di Maio, M Silletta, L D’Onofrio, C Spoto, MC Piccirillo, ... PloS one 10 (7), e0133488, 2015 | 151 | 2015 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 83 | 2022 |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population A Casadei-Gardini, M Rimini, T Tada, G Suda, S Shimose, M Kudo, ... European Journal of Cancer 180, 9-20, 2023 | 70 | 2023 |
| Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome B Vincenzi, D Santini, S Galluzzo, A Russo, F Fulfaro, M Silletta, ... Clinical cancer research 14 (13), 4219-4224, 2008 | 69 | 2008 |
| New frontiers in the medical management of gastrointestinal stromal tumours A Mazzocca, A Napolitano, M Silletta, M Spalato Ceruso, D Santini, ... Therapeutic Advances in Medical Oncology 11, 1758835919841946, 2019 | 62 | 2019 |
| Cell cycle alterations and lung cancer B Vincenzi, G Schiavon, M Silletta, D Santini, GM Perrone, M Di Marino, ... Histology and histopathology, 2006 | 61 | 2006 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 52 | 2021 |
| Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients B Vincenzi, D Santini, A Russo, M Silletta, M Gavasci, F Battistoni, ... Annals of oncology 17 (5), 835-841, 2006 | 47 | 2006 |
| The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib F Caputo, V Dadduzio, F Tovoli, G Bertolini, G Cabibbo, K Cerma, ... PLoS One 15 (5), e0232449, 2020 | 39 | 2020 |
| Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy V Burgio, M Iavarone, GG Di Costanzo, F Marra, S Lonardi, E Tamburini, ... Cancer Management and Research, 9379-9389, 2021 | 36 | 2021 |
| Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options B Vincenzi, AM Frezza, G Schiavon, D Santini, P Dileo, M Silletta, D Delisi, ... Clinical sarcoma research 3, 1-5, 2013 | 36 | 2013 |
| Immunotherapy in hepatocellular carcinoma CAM Fulgenzi, T Talbot, SM Murray, M Silletta, B Vincenzi, A Cortellini, ... Current Treatment Options in Oncology 22, 1-19, 2021 | 35 | 2021 |
| Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib M Rimini, M Kudo, T Tada, S Shigeo, W Kang, G Suda, A Jefremow, ... ESMO open 6 (6), 100330, 2021 | 32 | 2021 |
| Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials CAM Fulgenzi, B Scheiner, J Korolewicz, CV Stikas, A Gennari, ... JHEP Reports 5 (5), 100702, 2023 | 29 | 2023 |
| Antiangiogenic properties of metronomic chemotherapy in breast cancer G Tonini, G Schiavon, M Silletta, B Vincenzi, D Santini Future Oncology 3 (2), 183-190, 2007 | 27 | 2007 |
| Adjuvant imatinib in patients with GIST harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study B Vincenzi, A Napolitano, M Fiocco, O Mir, P Rutkowski, JY Blay, ... Clinical Cancer Research 28 (8), 1672-1679, 2022 | 26 | 2022 |
| Recent advances in desmoid tumor therapy A Napolitano, A Mazzocca, M Spalato Ceruso, A Minelli, F Baldo, ... Cancers 12 (8), 2135, 2020 | 26 | 2020 |
| Use of cardioprotective dexrazoxane is associated with increased myelotoxicity in anthracycline-treated soft-tissue sarcoma patients M Spalato Ceruso, A Napolitano, M Silletta, A Mazzocca, S Valeri, ... Chemotherapy 64 (2), 105-109, 2019 | 24 | 2019 |
| Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients M Persano, M Rimini, T Tada, G Suda, S Shimose, M Kudo, J Cheon, ... European Journal of Cancer 189, 112933, 2023 | 21 | 2023 |
